An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.

This research article studies a recombinant canarypox virus vaccine that can combat African horse sickness virus (AHSV) in horses. The study explores the cell-mediated immunity (CMI) triggered in the vaccinated horses and how it effectively aids in fighting off AHSV.

Objective and Methodology:

• The research was meant to delve into how a new vaccine based on the recombinant canarypox virus that expresses synthetic genes associated with specific proteins of the African horse sickness virus works to induce a certain immune response, namely cell-mediated immunity, in horses.
• The researchers carried out their study using a group of six horses who received two vaccinations twenty-eight days apart and a control group of three horses who were not vaccinated.

Vaccine Efficacy and Cell-Mediated Immunity:

• The vaccine, ALVAC(®)-AHSV4, generated significant production of IFN-γ, a substance that mediates immune responses, in the vaccinated horses, in stark contrast to the unvaccinated ones. This IFN-γ response correlates with the activation of cell-mediated immunity.
• Synthesized genes that relate to VP2 and VP5, the outer capsid proteins of the African horse sickness virus, were expressed in the vaccine. The cell-mediated immunity instigated by the vaccine recognized these proteins across all VP2 and only at the N-terminus sequence of VP5.

Findings and Conclusion:

• The results showed that in all the vaccinated horses, the vaccine induced immune cells, predominantly CD8(+) T cells, to recognize multiple T-epitopes across all VP2 and the N-terminus sequence of VP5, a phenomenon not observed in the controls. These T cells play a vital role in fighting viruses and other pathogens.
• The researchers conclude from their findings that the experimental canarypox-based vaccine activates significant cell-mediated immunity that is specific to both VP2 and VP5 proteins of the African horse sickness virus, thereby offering effective protection against this debilitating equine disease.